1,2-di-O-octadecenyl-3-trimethylammonium propane | 104872-42-6

• 物质功能分类: 表面活性剂 - 阳离子表面活性剂
• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,2-di-O-octadecenyl-3-trimethylammonium propane
• 英文别名: DOTMA；2,3-Bis(octadec-9-enoxy)propyl-trimethylazanium;chloride
• CAS: 104872-42-6
• 化学式: C₄₂H₈₄NO₂*Cl
• 分子量: 670.587
• InChiKey: LDGWQMRUWMSZIU-UHFFFAOYSA-M

物化性质

• 溶解度：
  DMSO:50.0(最大浓度 mg/mL);0.03(最大浓度 mM)

计算性质

• 辛醇/水分配系数(LogP)：
  10.17
• 重原子数：
  46
• 可旋转键数：
  37
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  1,2-di-O-octadecenyl-3-trimethylammonium propane 、 双(三氟甲基磺酰基)酰亚胺钾 以 水 为溶剂， 生成
  参考文献：
  名称：

  Structure-based tuning of Tm in lipid-like ionic liquids. Insights from Tf2N− salts of gene transfection agents

  摘要：

  研究表明，带有两个类脂脂族尾部的阳离子的离子液体的 Tm 值可以很低，而且可以通过添加、删除或组合双极模块和侧链双键来调高或调低 Tm 值。

  DOI：

  10.1039/c2cc33609j
• 作为产物：
  描述：

  甲醇 、 (2,3-bis-octadec-9-enyloxypropyl)-dimethylamine 在 氯甲烷磺酰氟 、 sodium carbonate 、 盐酸 作用下， 以 氯苯 为溶剂， 以89 %的产率得到1,2-di-O-octadecenyl-3-trimethylammonium propane
  参考文献：
  名称：

  CN116003271

  摘要：

  公开号：

文献信息

• Expression of exogenous polynucleotide sequences in a vertebrate
  申请人：VICAL, INC.

  公开号：EP1026253A2

  公开（公告）日：2000-08-09

  A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of an isolated polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.

  一种将分离的多核苷酸递送到脊椎动物细胞内部的方法，包括将分离的多核苷酸间隙导入脊椎动物的组织，多核苷酸被组织细胞吸收并对脊椎动物产生治疗效果。该方法可用于向脊椎动物的细胞提供治疗多肽，在体内翻译多核苷酸时提供免疫反应，提供反义多核苷酸，向脊椎动物的细胞提供受体，或提供过渡性基因治疗。
• Method for coating fine particle with lipid membrane
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2241308A2

  公开（公告）日：2010-10-20

  An object of the present invention is to provide a safe, convenient and efficient method for coating fine particles with lipid membrane. There is provided a method for coating fine particles with lipid membrane, characterized in that, the rate of a polar organic solvent in an aqueous solution containing the polar organic solvent where the fine particles are dispersed and lipid is dissolved, is decreased.

  本发明的目的是提供一种安全、方便和高效的细颗粒脂膜包衣方法。 本发明提供了一种为细小颗粒包覆脂质膜的方法，其特征在于，在含有极性有机溶剂的水溶液中，细小颗粒分散，脂质溶解，极性有机溶剂的溶解速率降低。
• CKAP5-GENE-SILENCING RNAI PHARMACEUTICAL COMPOSITION
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP3153172A1

  公开（公告）日：2017-04-12

  The present invention provides a composition for suppressing the expression of the CKAP5 gene, the composition comprising a lipid particle containing a double-stranded nucleic acid as a drug and a cationic lipid, the double-stranded nucleic acid having an antisense strand having a base sequence complementary to the sequence of at least 19 continuous bases in CKAP5 gene mRNA of any one of SEQ ID NOs: 1 to 6, the cationic lipid being represented by formula (I): wherein R1 and R2 are the same or different and are each linear or branched alkyl, alkenyl or alkynyl of 12 to 24 carbon atoms; L1 and L2 are the same or different and are each -CO-O- or -O-CO-; a and b are the same or different and are each 1 to 3; and R3 is a hydrogen atom, alkyl of 1 to 6 carbon atoms, or alkenyl of 3 to 6 carbon atoms; a medicament comprising the composition, and the like.

  本发明提供了一种抑制 CKAP5 基因表达的组合物，该组合物包括含有作为药物的双链核酸和阳离子脂质的脂质颗粒、 双链核酸具有反义链，其碱基序列与 SEQ ID NOs: 1 至 6 中任一项的 CKAP5 基因 mRNA 中至少 19 个连续碱基序列互补、 阳离子脂质由式(I)表示： 其中 R1 和 R2 相同或不同，各自为 12 至 24 个碳原子的直链或支链烷基、烯基或炔基； L1 和 L2 相同或不同，各自为-CO-O-或-O-CO-； a 和 b 相同或不同，且各自为 1 至 3；以及 R3 是氢原子、1 至 6 个碳原子的烷基或 3 至 6 个碳原子的烯基； 包含该组合物的药物等。
• METHOD OF MAKING LIPID NANOPARTICLES
  申请人：Polymun Scientific Immunbiologische Forschung GmbH

  公开号：EP3711749A1

  公开（公告）日：2020-09-23

  What is described is a method of producing lipid nanoparticles having an average diameter of less than 100 nm, comprising pumping an aqueous buffer solution through a 1st tube by a 1st HPLC pump, pumping an organic lipid solution through a 2nd tube by a 2nd HPLC pump, wherein the 2nd tube intersects the 1st tube perpendicularly within a mixing module, and wherein the organic lipid solution is mixed with the aqueous solution in a turbulent flow within the mixing module.

  所述的是一种生产平均直径小于 100 nm 的脂质纳米颗粒的方法，包括用第 1 HPLC 泵将缓冲水溶液泵入第 1 管，用第 2 HPLC 泵将有机脂质溶液泵入第 2 管，其中第 2 管在混合模块内与第 1 管垂直相交，有机脂质溶液在混合模块内以紊流方式与水溶液混合。
• COMPOSITION FOR INCREASING EXPRESSION OF BLOOD COAGULATION FACTOR GENE, COMPRISING CORE-SHELL STRUCTURED MICROPARTICLES AS ACTIVE INGREDIENT
  申请人：G&P Bioscience Co., Ltd.

  公开号：EP3753550A1

  公开（公告）日：2020-12-23

  The present disclosure relates to a composition for increasing the expression of a blood coagulation factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with blood coagulation factor VIII gene or a variant gene thereof, the composition for increasing the expression of a blood coagulation factor gene of the present disclosure can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.

  本公开涉及一种用于提高凝血因子基因表达的组合物，该组合物含有核壳结构微粒作为活性成分。当与血凝因子 VIII 基因或其变异基因一起在体内给药时，本公开的用于增加血凝因子基因表达的组合物可使该基因的表达量增加至少 30%。当与基因治疗剂一起给药时，该组合物即使使用极少量的基因也能达到治疗效果，因此非常有用。